Meeting
2013 ASCO Annual Meeting
EPIC: A phase III randomized, open-label study of ponatinib versus imatinib in adult patients with newly diagnosed chronic myeloid leukemia in chronic phase.
Authors
Jeffrey H. Lipton
Princess Margaret Hospital, Toronto, ON, Canada
Jeffrey H. Lipton , Michael W. N. Deininger , Stephanie Lustgarten , Christopher D. Turner , Victor M. Rivera , Tim Clackson , Michele Baccarani , Jorge E. Cortes , Francois Guilhot , Andreas Hochhaus , Timothy P. Hughes , Hagop M. Kantarjian , Neil P. Shah , Moshe Talpaz , Frank G. Haluska
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Leukemia, Myelodysplasia, and Transplantation
Track
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Sub Track
Leukemia
Clinical Trial Registration Number
NCT01650805
Citation
J Clin Oncol 31, 2013 (suppl; abstr TPS7129)
DOI
10.1200/jco.2013.31.15_suppl.tps7129
Abstract #
TPS7129
Poster Bd #
46A
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
EPIC: A phase III trial of ponatinib (PON) versus imatinib (IM) in patients (pts) with newly diagnosed CP-CML.
First Author: Jeffrey Howard Lipton
Poster
2019 ASCO Annual Meeting
Phase 3 PhALLCON study: Ponatinib (PON) versus imatinib (IM) with reduced-intensity chemotherapy (CT) in patients (pts) with newly diagnosed Philadelphia chromosome–positive (Ph+) ALL.
First Author: Elias Jabbour
Poster
2011 ASCO Annual Meeting
Dasatinib or imatinib (IM) in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): Two-year follow-up from DASISION.
First Author: H. Kantarjian
Poster
2016 ASCO Annual Meeting
4-year results of the ponatinib phase II PACE trial in patients (pts) with heavily pretreated leukemia.
First Author: Jorge E. Cortes